Estradiol metabolites for the treatment of pulmonary hypertension
US7192941B2 · kind B2 · utility
0Cited by
13References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 20, 2004 |
| Grant date | Mar 20, 2007 |
| Priority date | — |
| Expiry date | May 6, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0024
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods are provided for the treatment of pulmonary hypertension and other conditions associated therewith. In particular, the methods include treatment of pulmonary hypertension with estradiol metabolite or estradiol metabolite associated with biodegradable microparticles or nanoparticles alone or in combination with another therapeutic agent. Preferred estradiol metabolites include 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol, and 4-hydroxyestradiol, and/or to synthetic derivatives and analogues thereof or prodrugs thereof. The compositions may also be in the form of a controlled release formulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.